Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Stakes

<< Previous

Bullboard Posts

Next >>

Post by TheMadMonkon May 31, 2022 11:59am

160 Views

Post# 34720277

Stakes

I think that we should make this interesting, it can only be called a bet if there is something at stake. I would like to propose a winner stays; the loser goes kind of wager. If on September 23rd, 2022 the share price of ATE is at $0.45 or less, Mugsy stops posting in this chat room, however if the share price is at $0.46 or higher, Stutters agrees to never post again on the ATE board under any of his current or any new user names. Thoughts?

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record